A study to evaluate the effect of zigakibart in adults with IgA nephropathy
- Substances:Zigakibart
Germany- Participants:18–64 years · 65+ years
- Substances:Zigakibart
Rare diseases
Investigational molecules
Locations
GermanyA study of ulixertinib, tovorafenib, and vinblastine sulfate for children with progressive, relapsed, or refractory low-grade glioma
GermanyStudy of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer
GermanyA study to evaluate the safety and effectiveness of inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease
GermanyA study of pumitamig and a drug combination versus nivolumab and a drug combination for patients with untreated advanced or metastatic stomach or esophageal cancer
GermanyA study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer
GermanyComparison of CHF5993 (glycopyrronium bromide, formoterol fumarate dihydrate, and beclometasone dipropionate) and a drug combination for patients with mild to moderate asthma
GermanyA study of the humanised IgG1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1 to treat adults with idiopathic pulmonary fibrosis
GermanyA study of JNJ-78278343 and docetaxel compared to docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer
GermanyA Phase 3 study to evaluate the efficacy and safety of ION582 in children and adults with Angelman syndrome
GermanyA study evaluating the efficacy and safety of inavolisib and enzalutamide in patients with metastatic castration-resistant prostate cancer
GermanyA long-term safety study of KYV-101 in patients previously treated for lupus nephritis, systemic sclerosis, myasthenia gravis, rheumatoid arthritis, or stiff person syndrome
GermanyTell us about your condition – we search every trial in Europe and connect you with the right site.